This study was aimed at assisting the preoperative and non‐invasive prediction of HER2‐low breast cancer using multimodal ultrasound imaging and clinicopathological indicators, providing valuable imaging information for clinical precision diagnosis and personalized treatment strategies, especially in the application of antibody‐drug conjugates such as T‐DXd. Here, ERBB2 is linked to breast cancer.